期刊文献+

凯时和毫米波联合治疗糖尿病周围神经病变疗效观察 被引量:2

Clinical Study of Combined Therapeutic Effect of Lipo PGE_1 and Millimeter Wave on Diabetic Peripheral Neuropathy
在线阅读 下载PDF
导出
摘要 目的探讨前列腺素E1脂微球载体制剂(LipoPGE1,凯时)和毫米波联合治疗糖尿病周围神经病变的效果。方法将98例糖尿病周围神经病变患者随机分3组,分别为常规治疗组(对照组),凯时组(第1组),凯时和毫米波联合治疗组(第2组),观察治疗前后自觉症状,腱反射和神经传导速度。结果第2组总有效率为91%显著高于对照组(P<0.01),第1组总有效率为69%,与对照组比较有显著差异(P<0.05)。第2组神经传导速度治疗后较治疗前显著改善(P<0.01),而且显著优于第1组(P<0.05)。结论凯时联合毫米波治疗糖尿病周围神经病变较单独应用凯时有效。 Objective To study the clinical effect of combined treatment of Lipo PGEl and millimeter wave on diabetic peripheral neuropathy. Methods 98 patients with diabetic peripheral neuropathy(DPN) were randomly divided into the first treatment group with Lipo - PGE1, and the second treatment group combined with Lipo PGEl and millimeter wave compared with the routin therapy group as control in order to observe the subjective symptom, tendon reflex and nerve conduction velocity, respectively. Results The total effective rates of the second treatment group was 91% , which was significantly higher than the control group ( P 〈 0.01 ) , and the total effective rates of the first treatment group was 69% , which was significantly different from the control group ( P 〈 0.05 ) , The nerve conduction velocity of the second treatment group was improved significantly after therapy(P 〈0.01 ) , which was better than that of the first treatment group(P 〈0.05). Conclusions Combined therapy of Lipo PGE1 and millimeter wave is more effective than treatment of Lipo PGEl alone for the treatment of DPN.
出处 《医学研究杂志》 2007年第7期114-116,共3页 Journal of Medical Research
关键词 凯时 毫米波 糖尿病周围神经病变 Lipo PGE1 Millimeter wave Diabetic peripheral neuropathy
  • 相关文献

参考文献7

二级参考文献23

  • 1李剑波 陈家伟.糖尿病神经病变的发病机理及其现代认识[J].实用糖尿病杂志,1997,(5):3-3.
  • 2Cameron NE,Eaton SE,Cotter MA,et al.Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy.Diabetologia,2001,44:1973-1988.
  • 3Wada R,Nishizawa Y,Yagihashi N,et al.Effects of OPB-9195,anti-glycation agent,on experimental diabetic neuropathy.Eur J Clin Invest,2001,31:513-520.
  • 4Ziegler D.Therapy with antioxidants in human diabetic neuropathy.J Neurochem,2003,85(Suppl 2):15.
  • 5Takigawa T,Yasuda H,Terada M,et al.Increases in K+ conductance and Ca 2+influx under high glucose with suppressed Na+/K+-pump activity in rat myelinated nerve fibers.Neuroreport,2000,11:2547-2551.
  • 6Shimizu H,Ohtani KI,Tsuchiya T,et al.Aldose reductase mRNA expression is associated with rapid development of diabetic microangiopathy in Japanese type 2 diabetic (T2DM) patients.Diabetes Nutr Metab,2000,13:75-79.
  • 7Asano T,Saito Y,Kawakami M,et al.Fidarestat (SNK-860),a potent aldose reductase inhibitor,normalizes the elevated sorbitol accumulation in erythrocytes of diabetic patients.J Diabetes Complications,2002,16:133-138.
  • 8Cameron NE,Cotter MA.Vascular changes in animal models of diabetic neuropathy.J Neurochem,2003,85(Suppl 2):14.
  • 9Hounsom L,Corder R,Patel J,et al.Oxidative stress participates in the breakdown of neuronal phenotype in experimental diabetic neuropathy.Diabetologia,2001,44:424-428.
  • 10Purves T,Middlemas A,Agthong S,et al.A role for mitogen-activated protein kinases in the etiology of diabetic neuropathy.FASEB J,2001,15:2508-2514.

共引文献365

同被引文献43

引证文献2

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部